Welcome to Paid Research Studies

  • Condition:   Cancer
    Intervention:   Drug: CYC065
    Sponsor:   Cyclacel Pharmaceuticals, Inc.

  • Conditions:   Adult Solid Tumor;   Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Adult Central Nervous System Germ Cell Tumor;   Adult Teratoma;   Benign Teratoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Familial Testicular Germ Cell Tumor;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Male Breast Cancer;   Ovarian Immature Teratoma;   Ovarian Mature Teratoma;   Ovarian Monodermal and Highly Specialized Teratoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Extragonadal Germ Cell Tumor;   Recurrent Extragonadal Non-seminomatous Germ Cell Tumor;   Recurrent Extragonadal Seminoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Melanoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Rectal Cancer;   Stage III Extragonadal Non-seminomatous Germ Cell Tumor;   Stage III Extragonadal Seminoma;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Ovarian Germ Cell Tumor;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Extragonadal Non-seminomatous Germ Cell Tumor;   Stage IV Extragonadal Seminoma;   Stage IV Melanoma;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Rectal Cancer;   Testicular Immature Teratoma;   Testicular Mature Teratoma
    Interventions:   Drug: PD-0332991;   Other: pharmacological study
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania

  • Conditions:   Advanced Malignant Solid Neoplasm;   Metastatic Malignant Solid Neoplasm;   Unresectable Solid Neoplasm
    Interventions:   Drug: CDKI AT7519;   Other: Laboratory Biomarker Analysis;   Drug: Onalespib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)

  • Conditions:   Follicular Lymphoma (FL);   Mantle Cell Lymphoma (MCL);   Marginal Zone Lymphoma (MZL);   Small Lymphocytic Lymphoma (SLL);   Chronic Lymphocytic Leukemia (CLL);   Diffuse Large B-cell Lymphoma (DLBCL);   Acute Myeloid Leukemia (AML)
    Intervention:   Drug: Voruciclib
    Sponsor:   MEI Pharma, Inc.